Bioelectronics Corporation (BIEL) Stock Price & Analysis

Bioelectronics Corporation (BIEL) Healthcare & Pipeline Overview

BioElectronics Corporation is an electroceutical company focused on developing and commercializing wearable neuromodulation devices for pain management and quality of life improvement. Its product line targets human applications like musculoskeletal and menstrual pain, as well as veterinary uses, distributing to wholesale, clinical, and consumer channels globally.

What Is the Investment Thesis for BIEL?

BioElectronics Corporation (BIEL) operates in the specialized and growing electroceutical market, focusing on wearable neuromodulation devices for pain management. The company's diverse product line, including ActiPatch, Allay, Smart Insole, RecoveryRx, and HealFast, addresses both human and animal health, providing multiple avenues for revenue generation. With a gross margin of 73.3%, the company demonstrates strong product-level profitability, indicating efficient cost management for its core offerings. While the current profit margin stands at -187.6% and the market capitalization is $7.41M, suggesting early-stage or re-investment heavy operations, the high gross margin provides a foundation for future profitability if sales volume and operational efficiency scale. The beta of 2.07 indicates higher volatility compared to the broader market, which could appeal to investors seeking higher risk-reward profiles. Future growth catalysts include potential expansion into new therapeutic areas, increased adoption in professional medical settings, and broader international distribution, leveraging its existing product efficacy.

Based on FMP financials and quantitative analysis

BIEL Key Highlights

Market Capitalization of $7.41M, reflecting its current valuation as a micro-cap company.

• Gross Margin of 73.3%, indicating strong profitability on its core product sales before operating expenses.
• Profit Margin of -187.6%, highlighting significant operational losses relative to revenue, likely due to investment in R&D or sales infrastructure.
• Beta of 2.07, suggesting the stock's price is significantly more volatile than the overall market.
• A lean operational structure with 9 employees, indicating a focused and potentially agile organization.

What Are BIEL's Key Strengths?

Specialized focus on electroceutical wearable neuromodulation devices.

• Diverse product portfolio addressing both human and animal health applications.
• Strong gross margin of 73.3% on product sales.
• Established distribution channels including wholesale, medical, and direct-to-consumer.

What Are BIEL's Weaknesses?

Negative profit margin of -187.6% indicating significant operational losses.

• Small employee base of 9, potentially limiting scalability and R&D capacity.
• Market capitalization of $7.41M, reflecting a micro-cap status with potential liquidity challenges.
• High beta of 2.07 suggests significant stock price volatility.

What Are the Key Risks for BIEL?

Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.

• Continued negative profit margins could deplete capital and hinder future growth initiatives.
• Intense competition in the medical device and pain management markets from larger, more established players.
• Regulatory challenges or delays in obtaining approvals for new products or market expansions.
• Dependence on consumer and medical professional acceptance of electroceutical therapies as alternatives to traditional treatments.
• Limited financial disclosure and low liquidity due to OTC Other tier listing, posing risks for investors.

What Threats Does BIEL Face?

• Intense competition from established medical device companies and pharmaceutical firms.
• Regulatory hurdles and approval processes for new medical devices in various markets.
• Dependence on consumer and professional acceptance of electroceutical therapies.
• Potential for new, more effective or cheaper alternative pain management solutions to emerge.

What Are BIEL's Competitive Advantages?

• Specialization in electroceutical, wearable neuromodulation devices, representing a distinct technological focus.
• Established product portfolio addressing specific pain points (musculoskeletal, menstrual, heel pain) and animal health.
• Proprietary technology and intellectual property associated with its neuromodulation devices.
• Multi-channel distribution strategy reaching consumers, medical professionals, and wholesale partners globally.

What Does BIEL Do?

BioElectronics Corporation, established in 2000 and headquartered in Frederick, Maryland, operates as an electroceutical company dedicated to the development and global sale of wearable neuromodulation devices. These innovative devices are designed to mitigate various neurological diseases and enhance the overall quality of life for users. The company's product portfolio is diverse, addressing several key areas of pain management and recovery. For human applications, its flagship products include ActiPatch, a therapy specifically engineered for musculoskeletal pain; Allay, which provides targeted relief for menstrual pain; and Smart Insole, a specialized therapy for heel pain. Beyond consumer-focused solutions, BioElectronics Corporation also serves medical professionals with RecoveryRx, a medical device offering advanced pain management therapy. Demonstrating a broader scope, the company extends its electroceutical technology to the animal health sector with HealFast, a drug-free therapy designed for horses, cats, and dogs. HealFast aims to reduce swelling and pain, while also promoting the healing of muscle and tendon injuries, sores, and incisions in animals. The company employs a multi-channel sales strategy, distributing its products to wholesale distributors, hospitals and clinics, and directly to consumers worldwide, solidifying its position in the evolving electroceutical market.

What Products and Services Does BIEL Offer?

• Develops and sells wearable neuromodulation devices.
• Focuses on electroceutical solutions for pain management and quality of life enhancement.
• Offers ActiPatch for musculoskeletal pain therapy.
• Provides Allay for menstrual pain therapy.
• Markets Smart Insole for heel pain therapy.
• Supplies RecoveryRx, a medical device for pain management, to medical professionals.
• Produces HealFast, a drug-free therapy for pain and injury healing in horses, cats, and dogs.
• Distributes products globally through wholesale, hospital/clinic, and direct-to-consumer channels.

How Does BIEL Make Money?

• Generates revenue through the direct sale of proprietary wearable neuromodulation devices.
• Utilizes a multi-channel distribution strategy, including wholesale, B2B (hospitals/clinics), and B2C (consumers).
• Focuses on both human health applications (pain relief) and animal health applications (injury healing).
• Leverages its electroceutical technology platform across various product lines to address different market needs.

What Industry Does BIEL Operate In?

BioElectronics Corporation operates within the Medical Devices industry, a segment of the broader Healthcare sector characterized by continuous innovation in therapeutic technologies. The company's focus on electroceuticals and wearable neuromodulation devices positions it within a niche but expanding area of non-pharmacological pain management. This market is driven by increasing demand for drug-free alternatives, an aging global population, and advancements in bioelectronics. The competitive landscape includes both large pharmaceutical companies developing pain medications and other medical device firms offering alternative pain therapies, including TENS units and other neuromodulation technologies. BioElectronics Corporation differentiates itself through its specific wearable device form factors and targeted therapies for musculoskeletal, menstrual, and heel pain, as well as its unique foray into veterinary applications. The overall medical device market continues to grow, fueled by technological progress and a global emphasis on improved patient outcomes and quality of life.

Who Are BIEL's Key Customers?

• Wholesale distributors who then supply to retailers or other channels.
• Hospitals and clinics, particularly for professional-grade devices like RecoveryRx.
• Individual consumers seeking drug-free pain relief solutions for musculoskeletal, menstrual, and heel pain.
• Veterinarians and animal owners for pet and equine injury and pain management with HealFast.

Company Profile

Bioelectronics Corporation operates in the Healthcare sector. It is headquartered in Frederick, US. The company is led by CEO Kelly A. Whelan. BIEL has traded publicly since 2004.

Bioelectronics Corporation's Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

Return on equity for Bioelectronics Corporation stands at 5.5%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -3.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.01 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -12.6%, the inverse of the P/E and a quick read on earnings relative to price.

BIEL Valuation & Market Position

With a $7.41M market cap, Bioelectronics Corporation sits in the micro-cap segment of the market.

BIEL Financials

BIEL Latest News

No recent news available for BIEL.

BIEL Analyst Consensus

BIEL MoonshotScore

Common Questions About BIEL (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources